A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors

Inclusion Criteria: * Confirmed metastatic or unresectable, resistant solid tumor. Gynecologic tumors preferred. * 18 years and above * GOG performance status greater than or equal to 2 * Life expectancy greater than 6 months * Acceptable organ and marrow function * Willingness to agree to use adequate contraception prior to study entry and for the duration of study participation Exclusion Criteria: * Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or have not recovered from adverse events due to agents administered more than 4 weeks earlier * Not receiving any other investigational agents * Known brain metastasis * Uncontrolled intercurrent illness including, but not limited to ongoing ore active infection, symptomatic congestive heart failure, unstable angina pectoris,cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnancy * Immunosuppression including subjects with known HIV infection on immunosuppressive drugs or having an autoimmune disorder * Penicillin allergy * Symptomatic prostate hypertrophy